A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer

International Journal of Public Health

Volumn 56, Issue 2, 2011, Pages 153-162

  Demarteau, Nadia ^a   Detournay, Bruno ^a   Tehard, Bertrand ^b   El Hasnaoui, Abdelkader ^c   Standaert, Baudouin ^c  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b CEMKA EVAL   (France)

^c GLAXOSMITHKLINE   (France)

Author keywords

Cervical cancer; Cost effectiveness; Human papillomavirus; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CHILD; COHORT ANALYSIS; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; FRANCE; HUMAN; INCIDENCE; MORTALITY; PAPILLOMAVIRUS INFECTION; PROBABILITY; STATISTICAL MODEL; UTERINE CERVIX TUMOR; VACCINATION;

CHILD; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; FRANCE; HUMANS; INCIDENCE; MARKOV CHAINS; MODELS, ECONOMETRIC; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 79957467699     PISSN: 16618556     EISSN: 1420911X     Source Type: Journal    
DOI: 10.1007/s00038-010-0216-6     Document Type: Article

References (52)

1. Arveux P, Benard S, Bouee S, Lafuma A, Martin L, Cravello L, Remy V, Breugelmans JG (2007) Invasive cervical cancer treatment costs in France. Bull Cancer 94(2):219-224 (Pubitemid 46456117)
2. Beby-Defaux A, Bourgoin A, Ragot S, Battandier D, Lemasson JM, Renaud O, Bouguermouh S, Vienne Md ML, Agius G (2004) Human papillomavirus infection of the cervix uteri in women attending a Health Examination Center of the French social security. J Med Virol 73(2):262-268 (Pubitemid 38542681)
3. Bergeron C, Breugelmans JG, Bouee S, Lorans C, Benard S, Remy V (2006) Coût du depistage et de la prise en charge des lesions precancereuses du col uterin en France. Gynecologie Obstetrique Fertilite 34(11):1036-1042 (Pubitemid 44820918)
4. Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V (2008) Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care 24(1):10-19 (Pubitemid 351158538)
5. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55(4):244-265 (Pubitemid 34293391)
6. Boulanger JC, Sevestre H, Bauville E, Ghighi C, Harlicot JP, Gondry J (2004) Epidemiology of HPV infection. Gynecol Obstet Fertil 32(3):218-223 (Pubitemid 38375956)
7. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P (2001) Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 84(12):1616-1623 (Pubitemid 32612492)
8. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S (2003) Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88(1):63-73
9. Cochand-Priollet B, Vincent S, Vielh P (2004) Cytopathology in France. Cytopathology 15(3):163-166 (Pubitemid 38789238)
10. Coleman MP, Gatta G, Verdecchia A, Esteve J, Sant M, Storm H, Allemani C, Ciccolallo L, Santaquilani M, Berrino F (2003) EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 14(Suppl 5):v128-v149
11. Dalstein V, Riethmuller D, Sautiere JL, Pretet JL, Kantelip B, Schaal JP, Mougin C (2004) Detection of cervical precancer and cancer in a hospital population; benefits of testing for human papillomavirus. Eur J Cancer 40(8):1225-1232 (Pubitemid 38526342)
12. Debicki D, Ferko N, Demarteau N, Gallivan S, Bauch C, Anonychuk A, Mantovani L, Capri S, Chou CY, Standaert B, Annemans L (2008) Comparison of detailed and succinct cohort modeling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine 26(Suppl 5):F16-F28
13. Exbrayat C (2002) Col de l'utérus. In: Remontet L, Buemi A, Velten M, Jougla E, Esteve J (eds) Evolution de l'incidence et de la mortalité par cancer en France de 1978 à 2000. Institut de Veille Sanitaire. Departement Maladies Chroniques et Traumatismes, Saint-Maurice Cédex, pp 107-112
14. Fahey MT, Irwig L, Macaskill P (1995) Meta-analysis of Pap test accuracy. Am J Epidemiol 141(7):680-689
15. Ferlay J, Bray F, Pisani P, Parkin DM (2004) Globocan 2002: Cancer incidence, mortality and prevalence worldwide. IARC Press. Available via IARC. Accessed August 2008
16. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) GLOBOCAN 2008: Cancer incidence and mortality worldwide. International agency for research on cancer. Available via http://globocan.iarc.fr. Accessed June 2010
17. Gold MR, Franks P, McCoy KI, Fryback DG (1998) Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 36(6):778-792 (Pubitemid 128454315)
18. Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA (1999) The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med 130(2):97-107 (Pubitemid 29045357)
19. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E (2004) Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96(8):604-615 (Pubitemid 38584984)
20. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa-Clemens SA, Dubin G (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 367(9518):1247-1255
21. Insinga R, Glass A, Rush B. (2005) Health state transitions following an abnormal pap smear: implications for health utility assessment in cost-effectiveness analyses. (Abstract W-02 presented at 22nd International Papillomavirus Conference and Clinical Workshop 2005, Vancouver, Canada, April 30-May 6)
22. Institut National des Etudes Démographiques (2004) Taux de mortalité par sexe et âge en 2004. http://www.ined.fr. Accessed March 2008
23. Institute of Medicine (2000) Appendix 11: human papillomavirus. In: Stratton KR, Durch JS, Lawrence S (eds) Vaccines for the 21st century: a tool for decisionmaking. National Academy Press, Washington, p 213
24. ISPOR (2010) Pharmacoeconomic guidelines around the world. http://www.ispor.org/PEguidelines/index.asp. Accessed September 2010
25. Kim JJ, Brisson M, Edmunds WJ, Goldie SJ (2008) Modeling cervical cancer prevention in developed countries. Vaccine 26(Suppl 10):K76-K86
26. Kohli M, Ferko N, Martin A, Franco EL, Jenkins D, Gallivan S, Sherlaw-Johnson C, Drummond M (2007) Estimating the longterm impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 96(1):143-150 (Pubitemid 46094653)
27. Kulasingam SL, Myers ER (2003) Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290(6):781-789 (Pubitemid 37432955)
28. Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G (2009) Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 27(2): 127-147
29. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP (1998) Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 92(4 Pt 2):727-735 (Pubitemid 28440819)
30. Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, Miller S, Clayton L, Farhat S, Broering J, Darragh T, Palefsky J (2001) Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 285(23):2995-3002 (Pubitemid 32550118)
31. Munoz N, Castellsague X, Gonzalez ABd, Gissmann L (2006) Chapter 1. Human papillomavirus in the etiology of human cancer. Vaccine 24(Suppl 3):S1-S10
32. Myers ER, GreenS, Lipkus I (2004) Patient preferences for health states related to HPV infection: visual analog scale versus time trade-off elicitation. (Abstract no 542 presented at the Twentyfirst International Papillomavirus Conference, Mexico City, Mexico. February 20-27)
33. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Bezemer PD, Verheijen RH, Meijer CJ (2001) Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 358(9295):1782-1783 (Pubitemid 33153007)
34. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374(9686):301-314
35. Riethmuller D, Gay C, Bertrand X, Bettinger D, Schaal JP, Carbillet JP, Lassabe C, Arveux P, Seilles E, Mougin C (1999) Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction. Diagn Mol Pathol 8(3):157-164 (Pubitemid 29521908)
36. Rogoza RM, Ferko N, Bentley J, Meijer CJLM, Berkhof J, Wang KL, Downs L, Smith JS, Franco EL (2008) Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis. Vaccine 26(Suppl 5):F46-F58
37. Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R, Moscicki AB, Rosenfeld WD, Sullivan BJ, Thoming CS, Tyring SK, Wheeler CM, Dubin G, Schuind A, Zahaf T, Greenacre M, Sgriobhadair A (2009) Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebocontrolled trial up to 6.4 years. Lancet 374(9706):1975-1985
38. Sanders GD, Taira AV (2003) Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 9(1):37-48 (Pubitemid 36110201)
39. Schaffer P, Sancho-Garnier H, Fender M, Dellenbach P, Carbillet JP, Monnet E, Gauthier GP, Garnier A (2000) Cervical cancer screening in France. Eur J Cancer 36(17):2215-2220
40. Skinner R, Apter D, Chow SN, Wheeler C, Dubin G (2009) Crossprotection efficacy of Cervarix(tm) against oncogenic HPV types beyond HPV-16/18. (Abstract no O-29.01 presented at the 25th International Papillomavirus Conference, Malmö, Sweden, May 8-14)
41. Stanley M, Lowy DR, Frazer I (2006) Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine 24(Suppl 3):S106-S113
42. Suárez E, Smith JS, Bosch FX, Nieminen P, Chen CJ, Torvinen S, Demarteau N, Standaert B (2008) Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine 26(Suppl 5):F29-F45
43. Szarewski A (2010) HPV vaccine: Cervarix. Expert Opin Biol Ther 10(3):477-487
44. Tjalma W, Paavonen J, Naud P, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Garland S, Szarewski A, Romanowski B, Aoki D, Schwarz TF, Poppe WAJ, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G (2009) Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against abnormal cytology and low-grade histopathological lesions in an oncogenic HPVnave population. (Abstract no A-171-0004-01446 presented at the 16th International Meeting of the European Society for Gynaecological Oncology (ESGO), Belgrade, Serbia, October 11-14)
45. Trottier H, Franco EL (2006) The epidemiology of genital human papillomavirus infection. Vaccine 24(Suppl 1):S1-S15
46. Van De Velde N, Brisson M, Boily MC (2007) Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 165(7):762-775 (Pubitemid 46434599)
47. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1):12-19 (Pubitemid 29406813)
48. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices-modeling studies. Value Health 6(1):9-17 (Pubitemid 36228345)
49. Wellings K, Collumbien M, Slaymaker E, Singh S, Hodges Z, Patel D, Bajos N (2006) Sexual behaviour in context: a global perspective. Lancet 368(9548):1706-1728 (Pubitemid 46055217)
50. Wheeler C, HPV Patricia Study Group (2010) Efficacy of the AS04- adjuvanted HPV-16/18 vaccine in reducing abnormal cytology and against lesions associated with vaccine and non-vaccine oncogenic types: an analysis of women negative for specific HPV types at baseline. (Abstract presented at THE European Research Organisation on Genital Infection and Neoplasia (EUROGIN), Monte Carlo, Monaco, February 17-20)
51. WHO/ICO (2010) Information centre on HPV and cervical cancer. http://www.who.int/hpvcentre/statistics/dynamic/ico/DataQuery Select.cfm. Accessed February 2010
52. Zur Hausen H (1996) Roots and perspectives of contemporary papillomavirus research. J Cancer Res Clin Oncol 122(1):3-13